| Basics |
Edwards Lifesciences Corp
Edwards Lifesciences Corp is a part of the healthcare sector. The company specializes in the treatment of structural heart disease. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.
|
| IPO Date: |
April 3, 2000 |
| Sector: |
Healthcare |
| Industry: |
Health Care Equipment and Supplies |
| Market Cap: |
$48.93B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.98 | 1.07%
|
| Avg Daily Range (30 D): |
$1.12 | 1.35%
|
| Avg Daily Range (90 D): |
$0.80 | 1.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.4M |
| Avg Daily Volume (30 D): |
3.62M |
| Avg Daily Volume (90 D): |
3.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
89 |
| Avg Trade Size (Sh.) (30 D): |
61 |
| Avg Trade Size (Sh.) (90 D): |
64 |
| Institutional Trades |
| Total Inst.Trades: |
27,715 |
| Avg Inst. Trade: |
$6.1M |
| Avg Inst. Trade (30 D): |
$8.75M |
| Avg Inst. Trade (90 D): |
$8.36M |
| Avg Inst. Trade Volume: |
.15M |
| Avg Inst. Trades (Per Day): |
5 |
| Market Closing Trades |
| Avg Closing Trade: |
$21.5M |
| Avg Closing Trade (30 D): |
$55.71M |
| Avg Closing Trade (90 D): |
$53.07M |
| Avg Closing Volume: |
401.09K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.5
|
$.57
|
|
Diluted EPS
|
|
$.5
|
$.56
|
|
Revenue
|
$
|
$ 1.55B
|
$ 1.53B
|
|
Gross Profit
|
$
|
$ 1.21B
|
$ 1.19B
|
|
Net Income / Loss
|
$
|
$ 290.3M
|
$ 331.5M
|
|
Operating Income / Loss
|
$
|
$ 307.1M
|
$ 411.2M
|
|
Cost of Revenue
|
$
|
$ 345.2M
|
$ 344.4M
|
|
Net Cash Flow
|
$
|
$ -595.2M
|
$ 141.2M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 01, 2020:
3:1
|
|
Dec 14, 2015:
2:1
|
|
May 28, 2010:
2:1
|
|
|
|
